Theisen K, Jahrmärker H
MMW Munch Med Wochenschr. 1980 Jan 18;122(3):87-94.
The more recent antiarrhythmic drugs sometimes with more complex action extend the therapeutic possibilities. In addition, numerous other substances are in clinical trial. An ideal antiarrhythmic agent with a reliable action, persistent effective levels, easily absorbable and with few side effects is not found among them. The indication for therapy in ventricular extrasystole is made on the grounds of an ominous ECG criteria and a presumed clinical threat. Controversial results of lidocaine therapy of acute mayocardial infarction are possibly due to pharmacokinetic factors. For "inhomogeneous repolarization" with increased tendency to ventricular fibrillation inducing drugs should be avoided. Malignant cardiac rhythm irregularities possible leading to sudden death require systemic therapeutical testing. In this case, combinations of antiarrhythmic drugs have the highest effectiveness.
近期的抗心律失常药物有时作用更为复杂,拓宽了治疗的可能性。此外,还有许多其他物质正处于临床试验阶段。然而,在这些药物中尚未发现一种作用可靠、能维持有效血药浓度、易于吸收且副作用少的理想抗心律失常药物。室性期前收缩的治疗指征基于不祥的心电图标准和推测的临床威胁来确定。利多卡因治疗急性心肌梗死的结果存在争议,这可能归因于药代动力学因素。对于具有增加心室颤动倾向的“复极不均一性”,应避免使用诱发药物。可能导致猝死的恶性心律失常需要进行系统的治疗性试验。在这种情况下,联合使用抗心律失常药物的效果最佳。